240 County Road Ipswich, MA 01938-2723 Tel 978-927-5054 Fax 978-921-1350 www.neb.com info@neb.com

New England Biolabs Certificate of Analysis

Product Name: KasI

Catalog #: R0544S/L
Concentration: 5,000 units/ml

Unit Definition: One unit is defined as the amount of enzyme required to digest 1 µg of pBR322 DNA in 1 hour at 37°C in a total reaction

volume of 50 μ l.

 Lot #:
 0441511

 Assay Date:
 11/2015

 Expiration Date:
 11/2016

 Storage Temp:
 -20°C

Storage Conditions: 500 mM KCl, 20 mM Tris-HCl (pH 7.0), 0.1 mM EDTA, 1mM MgCl2, 50% Glycerol, 0.10% Triton X-100, 200 μ g/ml

BSA

Specification Version: PS-R0544S/L v1.0
Effective Date: 19 Mar 2015

Assay Name/Specification (minimum release criteria)	Lot #0441511
Exonuclease Activity (Radioactivity Release) - A 50 μl reaction in CutSmart TM Buffer containing 1 μg of a mixture of single and double-stranded [³ H] <i>E. coli</i> DNA and a minimum of 5 units of KasI incubated for 4 hours at 37°C releases <0.1% of the total radioactivity.	Pass
Ligation and Recutting (Terminal Integrity) - After a 20-fold over-digestion of pBR322 DNA with KasI, >95% of the DNA fragments can be ligated with T4 DNA ligase in 16 hours at 16°C. Of these ligated fragments, >95% can be recut with KasI.	Pass
Non-Specific DNase Activity (16 Hour) - A 50 μl reaction in CutSmart TM Buffer containing 1 μg of pBR322 DNA and a minimum of 5 Units of KasI incubated for 16 hours at 37°C results in a DNA pattern free of detectable nuclease degradation as determined by agarose gel electrophoresis.	Pass
Protein Purity Assay (SDS-PAGE) - KasI is >95% pure as determined by SDS PAGE analysis using Coomassie Blue detection.	Pass

Authorized by Derek Robinson 19 Mar 2015

nqa.
ISO 9001
Registered
Quality





Inspected by
Stephanie Cornelio
19 Nov 2015

^{*} The BSA in this product has been granted an EDQM "Certificate of Suitability" from the European Directorate for the Quality of Medicines (# R1-CEP-2003-204-Rev00) and has been granted a USDA Certificate for Export of Bovine Blood Plasma/Serum for Manufacture into Pharmaceutical Products.